[go: up one dir, main page]

WO2003010197A3 - Polynucleotides et polypeptides gmg-1 et leurs utilisations - Google Patents

Polynucleotides et polypeptides gmg-1 et leurs utilisations Download PDF

Info

Publication number
WO2003010197A3
WO2003010197A3 PCT/IB2002/003402 IB0203402W WO03010197A3 WO 2003010197 A3 WO2003010197 A3 WO 2003010197A3 IB 0203402 W IB0203402 W IB 0203402W WO 03010197 A3 WO03010197 A3 WO 03010197A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
gmg
related diseases
polynucleotides
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/003402
Other languages
English (en)
Other versions
WO2003010197A2 (fr
Inventor
John Lucas
Aaron Scalia
Deno Dialynas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to AU2002330672A priority Critical patent/AU2002330672A1/en
Publication of WO2003010197A2 publication Critical patent/WO2003010197A2/fr
Publication of WO2003010197A3 publication Critical patent/WO2003010197A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention a trait au domaine de la recherche contre l'obésité, problème de santé publique grave et répandu. Un composé, homotrimère d'un fragment de polypeptide GMG-1 comprenant un domaine globulaire et tout ou partie d'un domaine GMG-1 de type collagène, a été identifié ; ce dernier permet de réduire la masse corporelle, de maintenir la perte de poids, et de traiter des maladies et des troubles liés à l'obésité. Ces maladies et troubles liés à l'obésité comprennent les hyperlipidémies, l'athérosclérose, le diabète et l'hypertension.
PCT/IB2002/003402 2001-07-25 2002-07-23 Polynucleotides et polypeptides gmg-1 et leurs utilisations Ceased WO2003010197A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002330672A AU2002330672A1 (en) 2001-07-25 2002-07-23 Gmg-1 polynucleotides and polypeptides and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US30787601P 2001-07-25 2001-07-25
US60/307,876 2001-07-25
US30897901P 2001-07-30 2001-07-30
US60/308,979 2001-07-30
US30919701P 2001-07-31 2001-07-31
US60/309,197 2001-07-31
US31457501P 2001-08-23 2001-08-23
US60/314,575 2001-08-23

Publications (2)

Publication Number Publication Date
WO2003010197A2 WO2003010197A2 (fr) 2003-02-06
WO2003010197A3 true WO2003010197A3 (fr) 2003-06-05

Family

ID=27501940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/003402 Ceased WO2003010197A2 (fr) 2001-07-25 2002-07-23 Polynucleotides et polypeptides gmg-1 et leurs utilisations

Country Status (2)

Country Link
AU (1) AU2002330672A1 (fr)
WO (1) WO2003010197A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509545B8 (fr) 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Tete globulaire de obg3 etendue et homotrimere et utilisations associees
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20090291091A1 (en) * 2005-07-29 2009-11-26 Laboratoires Serono Sa Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
WO2007102736A2 (fr) * 2006-03-08 2007-09-13 Universitair Medisch Centrum Utrecht Procédé d'interférence dans l'activation d'une cellule immunitaire par commande de l'interaction entre lair et collagène
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP2015524422A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063381A1 (fr) * 1999-04-16 2000-10-26 Scios, Inc. Proteine mammalienne a fonction presumee de transduction de signaux
WO2001055356A2 (fr) * 2000-01-25 2001-08-02 Sugen, Inc. Nouvelles proteines kinases humaines et enzymes semblables aux proteines kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063381A1 (fr) * 1999-04-16 2000-10-26 Scios, Inc. Proteine mammalienne a fonction presumee de transduction de signaux
WO2001055356A2 (fr) * 2000-01-25 2001-08-02 Sugen, Inc. Nouvelles proteines kinases humaines et enzymes semblables aux proteines kinases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HU E ET AL: "AdipoQ is a novel adipose-specific gene dysregulated in obesity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 18, 3 May 1996 (1996-05-03), pages 10697 - 10703, XP002096544, ISSN: 0021-9258 *
MAEDA K ET AL: "CNDA CLONING AND EXPRESSION OF A NOVEL ADIPOSE SPECIFIC COLLAGEN- LIKE FACTOR, APM1 (ADIPOSE MOST ABUNDANT GENE TRANSCRIPT)", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 221, 1 April 1996 (1996-04-01), pages 286 - 289, XP000612064, ISSN: 0006-291X *
NAKANO Y ET AL: "Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma", JOURNAL OF BIOCHEMISTRY, JAPANESE BIOCHEMICAL SOCIETY, TOKYO, JP, vol. 120, no. 4, 1996, pages 803 - 812, XP002080710, ISSN: 0021-924X *
SCHERER P E ET AL: "A NOVEL SERUM PROTEIN SIMILAR TO C1Q, PRODUCED EXCLUSIVELY IN ADIPOCYTES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 45, 1 November 1995 (1995-11-01), pages 26746 - 26749, XP000612012, ISSN: 0021-9258 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
AU2002330672A1 (en) 2003-02-17
WO2003010197A2 (fr) 2003-02-06

Similar Documents

Publication Publication Date Title
WO2003010314A3 (fr) Polynucleotides et polypeptides gmg-2 et leurs utilisations
WO2003010197A3 (fr) Polynucleotides et polypeptides gmg-1 et leurs utilisations
PT1248849E (pt) Cabeça globular obg3 e suas utilizações para reduzir a massa corporal
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
EP1474139A4 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
PL367264A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
FR2823663B1 (fr) Dispositif de traitement de l'obesite morbide
MY139541A (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l'obesite, de maladies associees a l'insuline et de l'hypercholesterolemie
WO2002078614A3 (fr) Gene d'ancrage de type chs1/beige sensible au lps et applications therapeutiques de celui-ci
WO2003047507A3 (fr) Variants du domaine c2 du facteur viii
ATE204172T1 (de) Endothelin-rezeptorantagonisten zur bekämpfung von hyperlipidämie
EP1509545B8 (fr) Tete globulaire de obg3 etendue et homotrimere et utilisations associees
WO2003050281A3 (fr) Polynucleotides et polypetides gzip et leurs utilisations
WO2002058724A3 (fr) Utilisation de lp82 pour traiter les problemes de poids
EP0957111A3 (fr) Protéines de liaison spécifiques pour le traitement des allergies canines
WO2002066505A3 (fr) Polynucleotides et polypeptides gmg-3, gmg-4, et gmg-6 et utilisations associees
WO2002064782A3 (fr) Polypeptides de liaison de ligand rank -
WO2002060382A3 (fr) Composes et utilisations
WO2004039775A3 (fr) Antagonistes du recepteur il-8
BR0108749A (pt) Antagonistas de receptor il-8
WO2001060408A3 (fr) Micro-competition et maladie humaine
WO2003051911A3 (fr) Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci
WO2002020614A3 (fr) Polypeptide specifique de l'endogline, sa fabrication et son utilisation
WO2002068614A3 (fr) Protéine du facteur régulateur de l'interféron-1/de fusion réceptrice d'oestrogene humain et son utilisation dans le traitement des carcinomes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP